Clinical application of the measurement of serum asialoglycoproteins to estimate residual liver function in patients with chronic liver diseases with or without hepatocellular carcinoma

1985 ◽  
Vol 20 (3) ◽  
pp. 201-208 ◽  
Author(s):  
Takaya Sawamura ◽  
Shinobu Kawasato ◽  
Masanao Tsuda ◽  
Yuji Naitoh ◽  
Yasuko Shiozaki ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Function ◽  
Clinical Application ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Residual Liver Function

scholarly journals Novel Laboratory Tests in Assessment of Liver Function in Acute and Chronic Liver Diseases

2009 ◽  
Vol 63 (4-5) ◽  
pp. 228-233
Author(s):  
Ludmila Vīksna ◽  
Jāzeps Keišs ◽  
Artūrs Sočņevs ◽  
Baiba Rozentāle ◽  
Māra Pilmane ◽  
...  
Keyword(s):  
Liver Function ◽  
Liver Biopsy ◽  
Liver Diseases ◽  
Laboratory Tests ◽  
Serum Markers ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Noninvasive Methods ◽  
Disease Evolution ◽  
Prognostic Accuracy

Novel Laboratory Tests in Assessment of Liver Function in Acute and Chronic Liver Diseases Liver biopsy in clinical practice has been widely used for the diagnosis and management of patients with liver diseases, particularly, with chronic liver diseases. However, liver biopsy is an invasive method with potential complications, sampling and interpretation errors. Therefore, noninvasive tests are being developed and introduced to replace liver biopsy. The aim of the present study was to identify the new noninvasive methods to be used for the assessment of liver structure and function, by use of the appropriate serum surrogate markers and to evaluate the clinical diagnostic and prognostic accuracy of these methods, including immunogenetic methods, in cases of acute and chronic liver diseases. The obtained data showed that serum markers of apoptosis (cytokeratin-18 neoepitope and citochrome c) and fibrosis (hyaluronic acid) should be included in viral and toxic liver damage management algorithms. The punctual identification of immunogenetic factors (HLA class II antigens) may prove to be useful in predicting disease evolution, and in guiding the appropriate therapy for patients with poor prognosis.

scholarly journals Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma

2018 ◽  
Vol 10 (9) ◽  
pp. 558-570 ◽  
Author(s):  
Evangelista Sagnelli ◽  
Nicoletta Potenza ◽  
Lorenzo Onorato ◽  
Caterina Sagnelli ◽  
Nicola Coppola ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Micro Rnas ◽  
B Virus

Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases

Hepatology ◽  
2004 ◽  
Vol 41 (1) ◽  
pp. 40-47 ◽  
Author(s):  
Valérie Paradis ◽  
Francoise Degos ◽  
Delphine Dargère ◽  
Nanou Pham ◽  
Jacques Belghiti ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Serum Protein ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Protein Profiling ◽  
Chronic Liver Diseases

scholarly journals Quantitative Analysis of Aldolase A mRNA in Liver Discriminates between Hepatocellular Carcinoma and Cirrhosis

2000 ◽  
Vol 46 (7) ◽  
pp. 901-906 ◽  
Author(s):  
Giuseppe Castaldo ◽  
Giuseppe Calcagno ◽  
Raffaella Sibillo ◽  
Rosario Cuomo ◽  
Gerardo Nardone ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Quantitative Analysis ◽  
Hepatitis C ◽  
Liver Tissue ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Liver Biopsies ◽  
Aldolase A

Abstract Background: Chronic liver diseases can progress to cirrhosis and to hepatocellular carcinoma. Timely and unequivocal recognition of the neoplastic evolution of cirrhosis is critical. To this aim, we used a noncompetitive reverse transcription-PCR procedure to analyze aldolase A mRNA in liver tissue from patients with chronic liver diseases at different stages. Methods: We studied 12 patients with hepatocellular carcinoma, 19 patients affected by chronic hepatitis C or cirrhosis, and 7 healthy controls. Aldolase A mRNA was reverse-transcribed to cDNA, which was then amplified by PCR. The amplified segments were “read” with a novel dot-blot procedure. A calibrator with the same sequence, synthesized in vitro using a T7 phage promoter, was processed at scalar dilutions in parallel to the target samples to generate a calibration curve and so quantify the target mRNA (detection limit, 0.03 amol; linearity spanning five orders of magnitude). Results: Aldolase A mRNA was ∼10-fold higher in liver biopsies from patients with hepatocellular carcinoma vs patients with chronic hepatitis C or cirrhosis, and healthy individuals. Furthermore, aldolase A mRNA concentrations were 1.2- to 21.3-fold higher in 12 liver biopsies compared with the paired surrounding cirrhotic tissue. Conclusions: The quantitative analysis of liver tissue aldolase A mRNA differentiates between nonneoplastic chronic liver diseases and hepatocellular carcinoma, which suggests that it has diagnostic potential.

Sign in / Sign up

Export Citation Format

Share Document